Correlation Between Vivos Therapeutics and MaxCyte

Can any of the company-specific risk be diversified away by investing in both Vivos Therapeutics and MaxCyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vivos Therapeutics and MaxCyte into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vivos Therapeutics and MaxCyte, you can compare the effects of market volatilities on Vivos Therapeutics and MaxCyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vivos Therapeutics with a short position of MaxCyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vivos Therapeutics and MaxCyte.

Diversification Opportunities for Vivos Therapeutics and MaxCyte

0.69

Correlation Coefficient

Vivos Therapeutics  MaxCyte

Poor diversification

The 3 months correlation between Vivos and MaxCyte is 0.69. Overlapping area represents the amount of risk that can be diversified away by holding Vivos Therapeutics and MaxCyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on MaxCyte and Vivos Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vivos Therapeutics are associated (or correlated) with MaxCyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of MaxCyte has no effect on the direction of Vivos Therapeutics i.e., Vivos Therapeutics and MaxCyte go up and down completely randomly.

Pair Corralation between Vivos Therapeutics and MaxCyte

Given the investment horizon of 90 days Vivos Therapeutics is expected to under-perform the MaxCyte. In addition to that, Vivos Therapeutics is 1.41 times more volatile than MaxCyte. It trades about -0.03 of its total potential returns per unit of risk. MaxCyte is currently generating about 0.17 per unit of volatility. If you would invest  419.00  in MaxCyte on October 11, 2024 and sell it today you would earn a total of  38.00  from holding MaxCyte or generate 9.07% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Vivos Therapeutics  vs.  MaxCyte

Vivos Therapeutics

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Vivos Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile basic indicators, Vivos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

MaxCyte

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in MaxCyte are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental indicators, MaxCyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Vivos Therapeutics and MaxCyte

The main advantage of trading using opposite Vivos Therapeutics and MaxCyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vivos Therapeutics position performs unexpectedly, MaxCyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MaxCyte will offset losses from the drop in MaxCyte's long position.

The idea behind Vivos Therapeutics and MaxCyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.